REPEAT: Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
April 21, 2021 09:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research...
Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
April 21, 2021 04:05 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research...
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
April 06, 2021 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
March 29, 2021 07:02 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
MagicMed Industries to Present at the Q1 Virtual Investor Summit
March 19, 2021 08:15 ET
|
MagicMed Industries Inc.
CALGARY, Alberta, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- MagicMed Industries Inc. ("MagicMed" or the "Company"), a biotechnology company focused on creating novel psychedelic...
Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
February 25, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
February 19, 2021 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction
January 04, 2021 20:28 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi of Franciosi Consulting Ltd. has been intrigued with the growing interest in the use of psychedelic drugs for treating...
InvestorBrandNetwork Introduces PsychedelicNewsWire – A Technology Driven Communications Platform Focused on Emerging Market Opportunities in all Aspects of Psychedelics and Therapeutics
June 25, 2020 08:17 ET
|
InvestorBrandNetwork (IBN)
SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) -- (June 25, 2020) – via NetworkWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies...
Global Paraxylene Market to witness a CAGR of 6.7% during 2018-2024
July 25, 2018 02:35 ET
|
Energias Market Research
NEW YORK, July 25, 2018 (GLOBE NEWSWIRE) -- The global paraxylene market was valued at USD 38.5 billion in 2017 and is expected to reach USD 64.7 billion by 2024, witnessing a CAGR of 6.7% over the...